Pfizer (NYSE:PFE) is one of the world’s largest pharmaceutical companies, but at $22.59 per share as of this writing, the ...

Pfizer (PFE) closed the last trading session at $22.79, gaining 1.3% over the past four weeks, but there could be plenty of ...

We recently published a list of 13 Stock Predictions That Jim Cramer Got Completely Wrong. In this article, we are going to ...

Pfizer said on Tuesday it would generate $1.7 billion more in savings from cost cuts to its manufacturing and research ...

Albert Bourla said Pfizer is being "frugal" with investments because of the uncertainty surrounding tariffs.

The company disclosed revenue of $13.7 billion and adjusted earnings of $0.92 per share, compared to consensus estimates of ...

Unlike other companies grappling with evolving trade policy, Pfizer didn't revise its full-year outlook Tuesday.

Big pharmaceutical companies as well as smaller biotechs have been hoping to score a win in one of today's highest-growth ...

Reviewing PFE’s five-year history, the stock has experienced a balanced 50-50 distribution of positive and negative returns ...

Pfizer’s R&D organization has been in flux for almost two years now, since the $43 billion acquisition of ADC specialist ...

Pfizer Inc. is cutting at least another $1.2 billion from its spending while the company searches for its next big hit after ...

Pfizer's robust product pipeline and consistent R&D investments position it well for future growth. See why I rate PFE stock ...